competitive binding assay

com·pet·i·tive bind·ing as·say

general term for an assay in which a substance competes for labeled versus unlabeled ligand; following separation of free and bound ligand, the concentration of unlabeled ligand is inversely proportional to the amount of labeled bound ligand. Values are compared with known standards.
See also: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym(s): displacement analysis, saturation analysis

com·pet·i·tive bind·ing as·say

(kŏm-pet'i-tive bīnd'ing as'ā)
An assay in which a binder competes for labeled versus unlabeled ligand; following separation of free and bound ligand, the ligand is quantitated by relating bound and unbound ratios to known standards.
See also: enzyme-linked immunosorbent assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay
Mentioned in ?
References in periodicals archive ?
Binding to PPAR-a, PPAR-p/5 and PPAR-y was assessed using a competitive binding assay, with the study finding LBE had affinity for and activated the three PPARs at 0.
The anti-hyperglycaemic and antihyperlipidaemic effects of lemon balm
A detailed description of the PPAR[gamma] binding assay is provided in Supplemental Material, "PPAR[gamma] Competitive Binding Assay and Quality Assurance/Quality Control.
Characterizing the peroxisome proliferator-activated receptor (PPAR[gamma]) ligand binding potential of several major flame retardants, their metabolites, and chemical mixtures in house dust
Following the saturation assay, a set of competitive binding assay were performed in membrane expressing n opioid receptors, 5 opioid receptors and k opioid receptors to determine the binding affinity of mitragynine, using the tracer [[sup.
Determination of mitragynine bound opioid receptors
The PathHunter[TM] technology provides competitive binding assay pharmacology in a cell based assay platform.
Functional GPCR Profiling Services with More than 70 GPCR Targets: without Force Coupling
Following the saturation assay, a set of competitive binding assay were performed in membrane expressing [mu] opioid receptors, [delta] opioid receptors and [kappa] opioid receptors to determine the binding affinity of mitragynine, using the tracer [3H]diphrenorphin and [[sup.
Determination of mitragynine bound opioid receptors
I was convinced of the power of this new approach to evaporation control when our scientists used the technology described in our new patent to reduce the volume of an aqueous competitive binding assay from 350 uL to 100 pL, more than a million times smaller.
Picoliter Inc. Announces Patent on Formation of Multi-Layer Droplets
In collaboration with Novalon Pharmaceutical Corporation, Cubist will also be presenting data on the identification of potent inhibitor molecules discovered in a new high throughput screening competitive binding assay that overcomes obstacles inherent in the screening of novel targets.
Cubist Pharmaceuticals Describes New VITA(TM) Technology for Enabling Genomics for Drug Discovery
Therefore, we performed a competitive binding assay between [.
Atrazine binds to the growth hormone-releasing hormone receptor and affects growth hormone gene expression
12] content of the sequestered holo-TC is released under reducing and alkaline conditions, converted to the stable cyano form with potassium cyanide, and quantified in a competitive binding assay with [[sup.
Recombinant human intrinsic factor expressed in plants is suitable for use in measurement of vitamin [B.sub.12]
In the competitive binding assay reagent sets for total VEGF, ELISA plates usually are coated with goat antirabbit antibodies for capture of polyclonal rabbit antihuman VEGF antibody.
Pitfalls in the measurement of circulating vascular endothelial growth factor
The specimen showed much less interference in a competitive binding assay, suggesting that the interference was produced by weak antibodies that did not compete well with a specific antigen, but could bridge the capture and detection antibodies together in a two-site assay.
When is a heterophile antibody not a heterophile antibody? When it is an antibody against a specific immunogen
had special characteristics for the competitive binding assay kit (Wako, Osaka, Japan).
Estrogenicity of styrene oligomers: response to Ohno et al. (Correspondence)

Medical browser ?
Full browser ?